IXICO plc New contract with top 10 pharmaceutical company (8878N)
14 May 2018 - 4:00PM
UK Regulatory
TIDMIXI
RNS Number : 8878N
IXICO plc
14 May 2018
14 May 2018
IXICO plc
("IXICO" or the "Company")
New contract with top 10 pharmaceutical company
Providing specialist imaging clinical trials services in
Huntington's disease
IXICO plc (AIM: IXI), the digital technologies company serving
neuroscience, today announced that it has signed a new contract
with a top 10 pharmaceutical company, further expanding its
relationship with one of its existing clients. The contract value
is GBP1.0m over a three year term, with study planning and site
set-up activities starting in the next few months.
IXICO will provide its technology-enabled imaging services in a
natural history study of people with early manifest Huntington's
disease ("HD") to observe the natural progression of the disease.
IXICO will use its TrialTracker(TM) digital platform to standardise
the acquisition and collection of MRI scans, including advanced
functional MR imaging, from centres across Europe and North
America. IXICO will also apply its proprietary image analysis
algorithms, together with in-licenced algorithms from leading
academic centres, to measure neurological changes in study
participants.
HD is a rare genetic neurodegenerative disorder that affects
movement, cognition and behaviour. This is an area of significant
unmet medical need as there are currently no effective marketed
treatments. IXICO was first involved in HD studies in 2007,
supporting some of the early observational studies led by academic
centres in Europe and North America, which characterised the
progression of the disease. Since that date IXICO has been
successful in providing its clinical trials services to
pharmaceutical and biopharmaceutical companies working in this
important area of clinical development.
Giulio Cerroni, Chief Executive of IXICO, said: "Today's
announcement continues IXICO's successful track record in providing
neuroimaging clinical trial services for Huntington's disease,
representing our third new contract in this therapeutic area in the
current financial year. I am delighted that we continue to win new
business with existing clients which I believe demonstrates the
value placed by our customers on the unique combination of
technologies and scientific expertise that we provide."
For further information please contact:
IXICO plc
Giulio Cerroni, Chief Executive Officer Tel: +44 20 3763
Susan Lowther, Chief Financial Officer 7499
Shore Capital (Nomad and Broker) Tel: +44 20 7408
Edward Mansfield / Anita Ghanekar / Daniel 4090
Bush
FTI Consulting Limited (Investor Relations) Tel: +44 20 3727
Simon Conway/Mo Noonan 1000
About IXICO
IXICO is the digital technologies company serving neuroscience.
Our mission is to transform the pursuit of improving brain health
through the application of digital technologies to neuroscience.
IXICO's specialist data analytics services are used by the global
pharmaceutical industry to select participants for clinical trials,
assess the safety and efficacy of new drugs in development and in
post marketing surveillance. Our neurological disease focus
includes Alzheimer's disease, Huntington's disease, Multiple
Sclerosis, Parkinson's disease and our integrated digital platform
encompasses the entire drug development lifecycle. It is a scalable
and secure infrastructure for the capture and analysis of
regulatory compliant clinical data to enable sponsors to make
rapid, better informed decisions. IXICO is also collaborating with
partners to develop new companion digital health products targeted
at improving patient outcomes.
More information is available on www.IXICO.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
CNTGRGDUXSBBGID
(END) Dow Jones Newswires
May 14, 2018 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Historical Stock Chart
From Apr 2024 to May 2024
Ixico (LSE:IXI)
Historical Stock Chart
From May 2023 to May 2024